Conference Day 2
Day Two
Wednesday June 23 2021
9:55 am Chair’s Opening Remarks
Looking at the Preclinical Data for Next Generation BCMA Targeted Therapies
10:00 am Sharing the Development of HPN217: BCMA-targeting TriTAC®
Synopsis
- TriTAC®: Reviewing characteristics of a novel T-cell engager platform
- Evaluating HPN217 preclinical in vitro and in vivo data
- HPN217 Phase 1/2 Trial for Multiple Myeloma
10:30 am Preclinical Evaluation of ALLO-605, an Allogeneic BCMA TurboCAR T Cell Therapy for the Treatment of Multiple Myeloma
Synopsis
- ALLO-605 bears a Turbodomain that confers constitutive, CAR T cellintrinsic cytokine signaling
- ALLO-605 demonstrated increased potency and persistence, while maintaining a good safety profile
- Analyze these preclinical results and how they support clinical investigation of ALLO-605 for the treatment of multiple myeloma
11:00 am BCMA-ATAC: Introducing a Novel Mode of Action in Cancer Therapy
Synopsis
- Antibody-Targeted Amanitin-Conjugates (ATACs) introduce a new mode of action into oncology therapy.
- The inhibition of RNA polymerase II facilitates killing of dormant tumor cells (CSCs, TICs) and offers new treatment options for difficult to treat cancers and high-risk patients.
- The unique MoA in combination with a demonstrated safety profile and a biomarker for patient selection might pave the way for accelerated development & approval for patient groups with high therapeutic needs.
- HDP-101 is a BCMA-ATAC entering Phase I trials for Multiple Myeloma in 2021.
11:30 am How do we Generate Rigorous, Reproducible, & Submission Ready Flow Cytometry Data?
Synopsis
- Utility of flow cytometry in biotherapeutic development and evaluation
- How to mitigate errors in flow cytometric bioanalysis
- Improve reproducibility of flow cytometric data in clinical research
Designing Clinical Trials for BCMA Targeted Therapies
12:00 pm Morning Refreshments
12:30 pm Clinical & Translational Insights from the Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (ide-cel)
Synopsis
- Evaluating clinical trial results from phase 1 (CRB-401) and phase 2 (MM-001) trials
- Reviewing clinical correlates of efficacy and safety to ide-cel
- Reviewing translational correlates of safety and efficacy to ide-cel
1:00 pm Development of TNB-383B, a BCMA x CD3 Bispecific T-cell Redirecting Antibody, for the Treatment of Relapsed/ Refractory Multiple Myeloma
Synopsis
- Explore Teneobio’s Discovery Platform that identified our unique anti-CD3
- Discuss preclinical data that supported activity:toxicity uncoupling by TNB-383B
- Review clinical data from the escalation part of the FIH phase 1 clinical trial
1:30 pm Antibody Based BCMA Therapies
Synopsis
- Evaluate how antibody-based immunotherapies targeting BCMA show great promise in relapsed/refractory multiple myeloma
- The antibody-drug conjugate belantamab mafodotin has recently been approved for late line therapy and combination regimens in earlier lines are currently under clinical investigation
- Explore how T-cell engagers, such as BCMAxCD3 bispecific antibodies have produced high response rates in late line patients in early clinical trials and appear to challenge cell-based therapies as an off-the-shelf alternative
Delving into the Rationale of Combinations Studies for BCMA Therapies
2:00 pm Lunch
3:00 pm Session Reserved for JnJ
3:30 pm The Impact of Antigen Density & Stability on the Efficacy of BCMA Targeted Therapeutics
Synopsis
• Review preclinical findings that inform the use of gamma secretase
inhibitors in combination with BCMA targeted therapy
• Discuss the experience from first-in-human combinations of gamma
secretase inhibitor therapy with BCMA CAR-T Cells
• Discuss the impact of BCMA surface density and stability on treatment
response
4:00 pm Afternoon Break
Looking at the Past & Protecting the Future; Patient Perspective
4:30 pm Global Competition in BCMA-targeted Immunotherapy
Synopsis
- Multiple myeloma remain as an “incurable” cancer?
- Clinical progress of CAR-T therapy in multiple myeloma
- Competitive landscape of BCMA targeted therapy in early-stage commercial development
5:00 pm Review of Preliminary Clinical Trial Results with CART-ddBCMA
Synopsis
• CART-ddBCMA is a a genetically modified cell therapy utilizing a novel
synthetic binding domain that is computationally designed, highly
stable, and engineered to reduce immunogenicity
• Evaluate preliminary results of a phase 1 clinical trial of CART-ddBCMA
that indicate high rates of deep and durable responses in subjects with
relapsed/refractory multiple myeloma
• This presentation will review preclinical rationale, clinical trial results,
and next steps for CART-ddBCMA as well as the next generation ARCsparX
platform